Tuberculosis drug may work better than others in its class
(PLOS) Treatment of tuberculosis involves a combination of several drugs, sometimes including drugs from a class known as fluoroquinolones. Using computer simulations, scientists have shown that the fluoroquinolone known as moxifloxacin may be superior to two other commonly used fluoroquinolones, according to a new paper in PLOS Computational Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 17, 2017 Category: Infectious Diseases Source Type: news
FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye
The FDA issued a safety alert after serious adverse events were reported in at least 43 patients who received a compounded triamcinolone and moxifloxacin product by intravitreal injection.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
Paratek shares soar as antibiotic passes late-stage hurdle
Shares of Paratek Pharmaceuticals jumped in after-hours trading Monday after the Boston-based biotech said that its lead antibiotic drug had performed well in a Phase 3 study involving patients with hospital-acquired pneumonia.
The news comes a week after reporting positive data from a late-stage trial of an acne treatment.
Paratek (Nasdaq: PRTK) said the 774-patient study had showed that omadacycline was nearly as effective as another common antibiotic, moxifloxacin, in helping patients reduce… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 4, 2017 Category: Health Management Authors: Max Stendahl Source Type: news
Paratek shares soar as antibiotic passes late-stage hurdle
Shares of Paratek Pharmaceuticals jumped in after-hours trading Monday after the Boston-based biotech said that its lead antibiotic drug had performed well in a Phase 3 study involving patients with hospital-acquired pneumonia.
The news comes a week after reporting positive data from a late-stage trial of an acne treatment.
Paratek (Nasdaq: PRTK) said the 774-patient study had showed that omadacycline was nearly as effective as another common antibiotic, moxifloxacin, in helping patients reduce… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 4, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Avelox (Moxifloxacin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 8, 2016 Category: Drugs & Pharmacology Source Type: news
Yet Another Warning On Fluoroquinolone Antibiotic Side Effects
Rare but significant and debilitating side effects - tendon rupture, peripheral neuropathy - can occur with fluoroquinolone antibiotics like Avelox or Cipro. The FDA is now warning that some of these side effects can occur together and that use of these drugs should be restricted for most uncomplicated infections. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 1, 2016 Category: Pharmaceuticals Authors: David Kroll Source Type: news
FDA Calls for More Restrictions on Fluoroquinolone Use (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The risks for "disabling and potentially permanent" side effects associated with systemic fluoroquinolone antibacterials (e.g., ciprofloxacin, moxifloxacin) generally outweigh the benefits in patients with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 15, 2016 Category: Primary Care Source Type: news
Novel Antibiotic Shows Promise for Community-Acquired Pneumonia (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Oral solithromycin is noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia, according to an industry-funded, phase 3 trial published … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 8, 2016 Category: Primary Care Source Type: news
Advantages Claimed for Dropless Cataract SurgeryAdvantages Claimed for Dropless Cataract Surgery
Use of a combined triamcinolone/moxifloxacin compound improves therapeutic compliance, enhances prophylaxis against infection, and costs less than conventional eyedrops. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2015 Category: Consumer Health News Tags: Ophthalmology Article Source Type: news
Nanoparticle delivery maximizes drug defense against bioterrorism agent
Scientists from the California NanoSystems Institute at UCLA have developed a nanoparticle delivery system for the antibiotic moxifloxacin that vastly improves the drug’s effectiveness against pneumonic tularemia, a type of pneumonia caused by inhalation of the bacterium Francisella tularensis.
The study, which appears in the journal ACS Nano, shows how the nanoparticle system targets the precise cells infected by the bacteria and maximizes the amount of drug delivered to those cells.
Jeffrey Zink, distinguished professor of chemistry and biochemistry and a senior author on the study, developed the mesoporous silica nan...
Source: UCLA Newsroom: Health Sciences - November 6, 2015 Category: Universities & Medical Training Source Type: news
Avelox Approved for Plague
Title: Avelox Approved for PlagueCategory: Health NewsCreated: 5/8/2015 12:00:00 AMLast Editorial Review: 5/11/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 11, 2015 Category: Drugs & Pharmacology Source Type: news
Moxifloxacin Approved for Treating Plague (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The antibiotic moxifloxacin (Avelox) has been approved for the prevention and treatment of pneumonic plague … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 11, 2015 Category: Primary Care Source Type: news
FDA Expands Indication of Moxifloxacin (Avelox) for PlagueFDA Expands Indication of Moxifloxacin (Avelox) for Plague
The antibiotic comes with a boxed warning about serious adverse events, but given the deadly nature of plague, "the benefit...outweighs these potential risks," the agency said. FDA Approvals (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 9, 2015 Category: Emergency Medicine Tags: Infectious Diseases News Alert Source Type: news
FDA approves additional antibacterial treatment for plague
The U.S. Food and Drug Administration today approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 8, 2015 Category: American Health Source Type: news
Omadacycline Noninferior to Moxifloxacin for Pneumonia
Second study shows noninferiority to linezolid for acute bacterial skin and skin - structure infections (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Journal, Source Type: news
